Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-293-7 | CAS number: 56-86-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
- Endpoint:
- carcinogenicity: oral
- Type of information:
- other: SIDS
- Adequacy of study:
- other information
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- SIDS for L-Glutamic acid
- Author:
- OECD
- Year:
- 2 013
- Report date:
- 2013
- Reference Type:
- publication
- Title:
- The dietary administration of L-monosodium glutamate, DL-monosodium glutamate and L-glutamic acid to rats
- Year:
- 1 979
- Bibliographic source:
- Toxicology letters, 3, 71-78
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- GLP compliance:
- not specified
Test material
- Specific details on test material used for the study:
- International Minerals and Chemical Corp., Chicago
Test material equivalent to submission substance identity:
yes
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: 11-13 weeks old
- Weight at study initiation: 250-300 g
- Housing: housed in wire-mesh cages each holding 7 or 8 animals
- Diet: ad libitum
- Water: ad libitum
Administration / exposure
- Route of administration:
- oral: feed
- Duration of treatment / exposure:
- 2 years
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0.1 other: %
- Remarks:
- L-glutaminic acid nominal in diet, equal to 199 and 542 mg/kg bw/day for males, and 125 and 348 mg/kg bw/day for females
- Dose / conc.:
- 0.4 other: %
- Remarks:
- L-glutaminic acid nominal in diet, equal to 199 and 542 mg/kg bw/day for males, and 125 and 348 mg/kg bw/day for females
- No. of animals per sex per dose:
- control: 61 for male and 89 for female
0.1% L-glutamic acid: 40 for male and 35 for female
0.4% L-glutamic acid: 35 for male and 40 for female - Control animals:
- yes, plain diet
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Cage side observations checked in table [No.2] were included.
DETAILED CLINICAL OBSERVATIONS: Yes
BODY WEIGHT: Yes
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Daily group food intake was assessed.
OPHTHALMOSCOPIC EXAMINATION: Yes
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 241, 567 and 681 days
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: No data
- Parameters checked in table [No.3] were examined.
NEUROBEHAVIOURAL EXAMINATION: Yes - Sacrifice and pathology:
- After 63 days, 6 males and 6 females from the control group and 3 males and 3 females from each of the treated groups were killed and examined for gross and histological changes. Since none were observed, further planned interim sacrifices were abandoned, except for a group of 23 rats after 68 days.
Histological studies were made on the lungs, heart, thyroid, trachea, oesophagus, stomach, intestine, kidneys, liver, spleen, gonads and on any other tissue that appeared abnormal, and on any tumour. - Other examinations:
- Any individual that appeared on regular examination to have any abnormality, such as a tumour, dental anomaly, paralysis, pneumonia, atypical eye condition or general debility, was killed if survival appeared to be threatened.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Description (incidence):
- Combined % survival at this time was 57.3 for all test animals and 59.3 for controls.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Bodyweight gains of all rats proceeded at a normal rate and there were no significant between-group differences for either females or males, althoughthe supplemented groups were consistently ahead of controls.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Nor were there any significant differences in general behaviour or estimated food intake.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no between-group haematological variations. In males and females of all groups there was a slight tendency to monocytosis throughout the study, and in all female groups at 681 days a slight eosinophilia.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no between-group differences in organ weight analysis or in any other findings.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- The combined incidence of tumours was 40.1% for all test animals, and 42.4% for conrols. The tumours in females were almost all mammary adenomata, some of which were actively secreting and some fibrosed. In males, most tumours were of dermal origin and classified as benign.
- Description (incidence and severity):
- The only significant difference was a 6.9% incidence of dental abnormalities in control rats, contrasted with 3.5% for all test rats combined.
Applicant's summary and conclusion
- Conclusions:
- There was no evidence that L-glutamic acid, at either dose level, exerted any adverse effect upon survival, weight increase, food intake, haematology, tumor incidence or age-related pathological changes in either sex. Motor activity and general behavioural patterns appeared unaffected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.